All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: ICON Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): 177Lu lilotomab satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
Data from this cohort is expected in H1'2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin®/40mg lilotomab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The study found that Betalutin (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The data presented in this paper are aligned with the preliminary results presented by Dr Kolstad at the American Society of Hematology medical conference in December 2018:Overall response rate (ORR) was 61% and complete response (CR) was 30% for all 74 patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
PARADIGME is the company's ongoing global, randomised Phase 2b trial investigating Betalutin® (177Lu-lilotomab satetraxetan) as a single administration in patients with 3rd-line relapsed / anti-CD-20-refractory FL who have received two or more prior therapies (3L R/R FL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alpha37
Therapeutic Area: Oncology Product Name: Alpha37
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Alpha37 is an investigational radioimmunoconjugate developed by Nordic Nanovector in collaboration with Orano Med comprising a proprietary chimeric CD37-targeting antibody conjugated to the alpha-particle generating radionuclide lead-212.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
Streamlined strategy with all resources focused on PARADIGME- all other trials to be suspended following completion of the current cohorts and all investments in pre-clinical assets to be halted.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
